Details

Autor(en) / Beteiligte

• Georgsson, Jennie
• Bergström, Fredrik
• Nordqvist, Anneli
• Watson, Martin J
• Blundell, Charles D
• Johansson, Magnus J
• Petersson, Annika U
• Yuan, Zhong-Qing
• Zhou, Yiqun
• Kristensson, Lisbeth
• Kakol-Palm, Dorota
• Tyrchan, Christian
• Wellner, Eric
• Bauer, Udo
• Brodin, Peter
• Svensson Henriksson, Anette

Titel

GPR103 Antagonists Demonstrating Anorexigenic Activity in Vivo: Design and Development of Pyrrolo[2,3‑c]pyridines That Mimic the C‑Terminal Arg-Phe Motif of QRFP26

Ist Teil von

• Journal of medicinal chemistry, 2014-07, Vol.57 (14), p.5935-5948

Ort / Verlag

United States: American Chemical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• GPR103, a G-protein coupled receptor, has been reported to have orexigenic properties through activation by the endogenous neuropeptide ligands QRFP26 and QRFP43. Recognizing that central administration of QRFP26 and QRFP43 increases high fat food intake in rats, we decided to investigate if antagonists of GPR103 could play a role in managing feeding behaviors. Here we present the development of a new series of pyrrolo[2,3-c]pyridines as GPR103 small molecule antagonists with GPR103 affinity, drug metabolism and pharmacokinetics and safety parameters suitable for drug development. In a preclinical obesity model measuring food intake, the anorexigenic effect of a pyrrolo[2,3-c]pyridine GPR103 antagonist was demonstrated. In addition, the dynamic 3D solution structure of the C-terminal heptapeptide of the endogenous agonist QRFP26(20–26) was determined using NMR. The synthetic pyrrolo[2,3-c]pyridine antagonists were compared to this experimental structure, which displayed a possible overlay of pharmacophore features supportive for further design of GPR103 antagonists.